Alnylam Pharmaceuticals Inc (ALNY) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Industry, else..
 
Alnylam Pharmaceuticals Inc   (NASDAQ: ALNY)
 

Alnylam Pharmaceuticals Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALNY Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) 66.86 % 12.24 % 9.19 % 10.9 %
Q / Q Revenue Growth (Q2 MRQ) 10.6 % -2.93 % -3.28 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) 95.14 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) 12.07 % 2.69 % 2.03 % 2.61 %
Revenue 5 Year Average Growth 49.77 % 7.41 % 8.65 % 10.59 %


ALNY's Growth Comparisons in II. Quarter 2026




Facing 66.86% year on year sales decrease in the second quarter 2026, to $ 1.29 billions, Alnylam Pharmaceuticals Inc reported smaller declines than the Major Pharmaceutical Preparations industry with 12.24%, and less than 9.19% growth in the Healthcare sector. Comparing the second quarter sales growth, both the Major Pharmaceutical Preparations industry and Alnylam Pharmaceuticals Inc outperformed 10.9% overall market increase.

Top-line improved by 10.6% from the first quarter. Looking into annual sales rise of 49.77%, and S & P 500's average yearly sales growth is 10.59% over the five years, including only Businesses with the second quarter 2026 Results. Alnylam Pharmaceuticals Inc grew faster than the market.

ALNY Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Net product revenues
54.14 %
0 %
Net revenues from collaborations
33.46 %
0 %
United States GIVLAARI
-11.2 %
-0.24 %
United States OXLUMO
5.91 %
0 %
Europe OXLUMO
11.22 %
0 %
Rest of World OXLUMO
11.68 %
0 %
AMVUTTRA
80.9 %
0 %
Europe GIVLAARI
-2.31 %
0.94 %
Total TTR
67.2 %
0 %
Rest of World AMVUTTRA
97.13 %
0.45 %
OXLUMO
9.49 %
0 %
Total Rare
-1.57 %
0 %
Roche Roche Development Services Obligation Roche Collaboration and License Agreement
106.15 %
0 %
Roche Other Roche Collaboration and License Agreement
-21.69 %
0 %
Regeneron Pharmaceuticals Research Services Obligation Global Strategic Collaboration
-48.81 %
0 %
Regeneron Pharmaceuticals Other license programs Global Strategic Collaboration
102.72 %
0 %
Total
66.86 %
10.6 %


Growth Rates of ALNY's Income in the second quarter 2026


ALNY Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) - -8.69 % 5.13 % 97.6 %
Sequential Operating Income Change (Q2 MRQ) -13.85 % -4.52 % 0.89 % 48.13 %
Y / Y Operating Income Growth (Q2 TTM) - 30.63 % 30.7 % 40.67 %
Sequential Operating Income Growth (Q2 TTM) 32.92 % -2.27 % 4.82 % 20.86 %
Operating Income 5 Year Avg. Change - 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) - -34.78 % -25.81 % 90.69 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) -20.15 % -2.61 % -66.16 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) - 6.3 % 2.68 % 57.33 %
Sequential Income from Cont. Ops. Change (Q2 TTM) 42.9 % -10.02 % -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - -0.55 % 0.17 % -28.52 %

ALNY Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) - -35.13 % -26.29 % 90.69 %
Q / Q Net Income Growth (Q2 MRQ) -20.15 % 2.8 % -0.86 % 27.07 %
Y / Y Net Income Change (Q2 TTM) - 5.21 % 15.47 % 57.33 %
Sequential Net Income Change (Q2 TTM) 41.44 % -10.17 % -6.74 % 18.65 %
Net Income 5 Year Avg. Growth - 14.55 % 9.21 % 22.96 %

ALNY's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) - -40.16 % -25.81 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) -20.65 % -7.73 % -66.16 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) 42.75 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - -10.79 % 0.17 % -28.52 %



ALNY EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) - -40.49 % -26.29 % -28.52 %
Q / Q EPS Net Growth (Q2 MRQ) -19.87 % -2.61 % -0.86 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) 27.25 % - 0.15 % 4.93 %
EPS Net 5 Year Avg. Change - 14.55 % 9.21 % 22.96 %



Alnylam Pharmaceuticals Inc reported bottom-line of $ 1.21 in the second quarter, compare to $ 0.00 in the same quarter a year ago. Major Pharmaceutical Preparations industry fell by -40.49%, while Healthcare sector decreased by -26.29%, and overall market improved by 90.69%.

Comparing the company's EPS to the first quarter results, income per share were lower by -19.87% . On the annual basis, average annual income per share growth for Alnylam Pharmaceuticals Inc is 49.77%, while S & P 500's including only Businesses with the second quarter 2026 financial reports, average yearly income per share growth is 22.96% over the past five years.

ALNY Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) 109.45 % 25.53 % 48.48 % 48.62 %
Sequential Free Cash Flow Change (Q2 MRQ) 500.04 % -42.35 % -46.96 % 34.18 %
Y / Y Free Cash Flow Change (Q2 TTM) - 11.91 % 18.61 % 60.27 %
Sequential Free Cash Flow Change (Q2 TTM) 23.8 % 3.24 % 5.39 % 15.75 %
Free Cash Flow 5 Year Avg. Change - 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q2 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q2 TTM) 312.36 % - - 209.43 %
Sequential Net Cash Flow Change (Q2 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) 142.64 % 11.25 % 8.23 % 120.03 %
Sequential Capital Expenditures Change (Q2 MRQ) 58.84 % -25.6 % -22.09 % 36.87 %
Y / Y Capital Expenditures Change (Q2 TTM) 151.57 % 16.65 % 7.86 % 109.38 %
Sequential Capital Expenditures Change (Q2 TTM) 28.49 % 2.92 % 1.6 % 23.05 %
Capital Expenditures 5 Year Avg. Change -3.56 % 7.84 % 8.61 % 14.74 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.